Cell reportsHumansCyclin-Dependent Kinase 6Cyclin-Dependent Kinase 4FemaleRetinoblastoma Protein
CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling.
Robin Minati, Maxime Cahuzac, Julie Perrault, Véronique Lullier, Anca Apavaloaei, Eric Bonneil, Mathieu Courcelles, Joel Lanoix, Eralda Kina, Claude Perreault, Pierre Thibault
Published: 202510.1016/j.celrep.2025.116676
Abstract
The cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are standard-of-care therapies for metastatic hormone receptor-positive (HR+) breast cancer, yet their immunomodulatory effects remain underexplored. Here, we demonstrate that CDK4/6 inhibition wi…
Preview only. Read the full abstract at the source